Bluejay Diagnostics, Inc. Enters into Securities Purchase Agreement

Bluejay Diagnostics, Inc. has entered into a securities purchase agreement for a private placement. The agreement involves the issuance and sale of 62,500 shares of the Company's common stock at a price of $2.00 per share. The transaction, which closed on March 17, 2026, generated aggregate gross proceeds of $125,000 for the Company. The purchasers in this private placement include key executives and board members: Neil Dey (President and CEO), Donald Chase (Chair of the Board), Svetlana Dey, Douglas Wurth, and Fred Zeidman. Each of these individuals purchased 12,500 shares for their personal accounts. The sale was conducted as a private placement under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D, with all purchasers represented as "accredited investors." The Company did not agree to provide registration rights for these securities. This filing also incorporates information regarding the unregistered sales of equity securities and lists the relevant exhibits, including the Securities Purchase Agreement.